Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00614653 · ClinicalTrials.gov registry record · Phase 1
Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00614653: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00614653 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 17 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00614653, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of capecitabine, erlotinib hydrochloride, and bevacizumab that can be given in combination with radiation to patients with pancreatic cancer.
Primary Outcome
Any of these events considered a dose-limiting toxicity. 1. Any grade 4 hemorrhage, grade 2 pulmonary or CNS hemorrhage 2. Cardiac arrhythmia 3. Grade 4 congestive heart failure 4. Grade 4 hypertension or reversible posterior leukoencephalopathy syndrome (RPLS) 5. Grade 4 nephrotic syndrome 6. Grade 4 diarrhea 7. Grade 4 rash 8. Pulmonary adverse event related to erlotinib 9. Bowel perforation 10. Symptomatic Grade 4 venous thromboembolic event, or any grade arterial thromboembolic event 11. Wo
Interventions
- DRUG Bevacizumab
- DRUG Capecitabine
- RADIATION Radiation Therapy
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2008-01 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
What the finished NCT00614653 record still lists
NCT00614653 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT00614653 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00614653 about?
NCT00614653 is a clinical study titled "Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer". The goal of this clinical research study is to find the highest tolerable dose of capecitabine, erlotinib hydrochloride, and bevacizumab that can be given in combination with radiation to patients with pancreatic cancer.
What is the current status of trial NCT00614653?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2008-01. Estimated completion is 2016-07.
What interventions are being tested in trial NCT00614653?
The interventions under investigation include: Bevacizumab (DRUG), Capecitabine (DRUG), Radiation Therapy (RADIATION), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00614653?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00614653's enrollment target sits among peer trials
17 1785th of 2000 higher than 215 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia